Home / News Update  / Pfizer started the study of mRNA flu vaccine

Pfizer started the study of mRNA flu vaccine

On Monday Pfizer Inc (PFE.N) said that it had dosed the first patient in a trial testing a flu vaccine based on messenger RNA, the same technology used in the COVID-19 shots made by the U.S. drugmaker

On Monday Pfizer Inc (PFE.N) said that it had dosed the first patient in a trial testing a flu vaccine based on messenger RNA, the same technology used in the COVID-19 shots made by the U.S. drugmaker and BioNTech .

Conducted in the United States, the early-stage vaccine trial will be tested the in healthy adults ages 65- 85.

Kathrin Jansen, head of vaccine research and development at Pfizer  said, “The COVID-19 pandemic allowed us to deliver on the immense scientific opportunity of mRNA. Influenza remains an area where we see a need for vaccines,”.

The study will test the safety and immune responses of the vaccine, compared to another FDA-approved influenza vaccine.

medgatetoday@gmail.com

Review overview
NO COMMENTS

POST A COMMENT